{"url_path":"/sec/aktx/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","accession_number":"0001493152-26-024446","cik":"0001541157","ticker":"AKTX","issuer_name":"Akari Therapeutics Plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","primary_entity_key":"0001541157","primary_entity_name":"Akari Therapeutics Plc"},"word_count":60,"has_tables":true,"body_markdown":"** **\n\n**Item\n1. Legal Proceedings.**\n\n** **\n\nFrom\ntime to time, we may become involved in litigation relating to claims arising out of operations in the normal course of business, which\nwe consider routine and incidental to our business.\n\n \n\nRefer\nto Note 13 of the Notes to our condensed consolidated financial statements related to commitments and contingencies, which is incorporated\nherein by reference."}